Zabrowski Dan 4

What Happened

• Dan Zabrowski, a director of Actuate Therapeutics, was granted a derivative award of 15,000 shares (reported as $0.00 consideration) on 2026-05-21. The Form 4 records this as an award/grant (derivative instrument), not a sale or open-market purchase, so there was no cash exchanged in the filing.

Key Details

• Transaction date: 2026-05-21; Form 4 filed 2026-05-22 (filed timely the next day).
• Instrument: 15,000 derivative shares reported as acquired at $0.00 (code A — award/grant).
• Cash amount reported: $0.00 (no cash paid at grant per the Form 4).
• Shares owned after transaction: not specified in the provided filing.
• Footnote: Options will vest in full on the anniversary of the grant date.
• Filing timeliness: Not marked late; filed the day after the transaction.

Context

• This was a grant of derivative securities (appears to be options) rather than an exercise or market purchase — there was no immediate sale of shares or cashless exercise. Vesting in full on the one-year anniversary means the recipient must wait until vesting before the award becomes exercisable/convertible under typical terms. For full economic terms (exercise price, expiration, restrictions), refer to the company's grant agreement or proxy/press release disclosures.